Child Development Disorders, Pervasive Clinical Trial
Official title:
Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders
Verified date | October 2016 |
Source | Université de Montréal |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
Children with autism spectrum disorders often engage in problem behaviors such as self-injury, destruction, aggression, and stereotypy. Prior research has clearly shown that these problem behaviors may interfere with learning, daily functioning, and social participation. As such, engaging in problem behaviors has a negative impact on the health and quality of life of children with autism spectrum disorders and their families. One promising solution to reduce problem behaviors in this population is the Prevent-Teach-Reinforce (PTR) model, which relies on the evidence-based practices of positive behavior support. Although the use of PTR has been gaining considerably support in schools, the model has never been evaluated as part of a rigorous large-scale study using parents as interventionists. Thus, the purpose of the project is to conduct an assessment of the effectiveness of a home-based version of the PTR model in reducing problem behaviors in children with autism spectrum disorders and in improving families' quality of life. Our hypotheses are that implementing the PTR will (a) produce larger reductions in problem behaviors than participating in an individual parent training session, (b) increase engagement in prosocial behaviors, (c) decrease parental stress, and (c) improve the quality of life of the family. The results of the study will allow an examination of whether PTR is an effective and acceptable model to reduce problem behaviors at home in this population. Given that problem behaviors incur high societal costs when they persist into adolescence and adulthood, the study may potentially lead to large cost reductions in the treatment of difficulties associated with autism spectrum disorders. By reducing engagement in problem behaviors, the implementation of the model may also promote and facilitate the social participation as well as improve the quality of life and health of children with autism spectrum disorders and their families.
Status | Completed |
Enrollment | 42 |
Est. completion date | September 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 12 Years |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of autism spectrum disorder - Must exhibit problem behavior Exclusion Criteria: - Already receiving services to reduce problem behaviors at home |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | West Montreal Readaptation Centre | Lachine | Quebec |
Canada | Gold Centre | Montreal | Quebec |
Canada | CRDITED de Montréal | Montréal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Université de Montréal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in parental report of problem behavior at 8 weeks | Problem behavior scale of the Problem Behavior Inventory | Prior to the start of the intervention and 8 weeks later | No |
Secondary | Change from baseline in quality of life at 8 weeks | Beach Center Family Quality of Life Scale | Prior to the start of the intervention and 8 weeks later | No |
Secondary | Change from baseline in parental report of stress at 20 weeks | Parenting Stress Index Short Form | Prior to the start of the intervention and 20 weeks later | No |
Secondary | Change from baseline in parental report of stress at 8 weeks | Parenting Stress Index Short Form | Prior to the start of the intervention and 8 weeks later | No |
Secondary | Change from baseline in quality of life at 20 weeks | Beach Center Family Quality of Life Scale | Prior to the start of the intervention and 20 weeks later | No |
Secondary | Social validity of the intervention | Treatment Acceptability Rating Form - Revised | After 8 weeks of intervention | No |
Secondary | Change from baseline in parental report of problem behavior at 20 weeks | Problem behavior scale of the Problem Behavior Inventory | Prior to the start of the intervention and 20 weeks later | No |
Secondary | Change from baseline in parental report of positive social behavior at 20 weeks | Positive social behavior scale of the Nisonger Child Behavior Rating Form | Prior to the start of the intervention and 20 weeks later | No |
Secondary | Change from baseline in parental report of positive social behavior at 8 weeks | Positive social behavior scale of the Nisonger Child Behavior Rating Form | Prior to the start of the intervention and 8 weeks later | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03222375 -
SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
|
N/A | |
Completed |
NCT01233414 -
Randomized Trial of Parent Training for Young Children With Autism
|
N/A | |
Completed |
NCT00926471 -
Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders
|
Phase 1 | |
Withdrawn |
NCT00376194 -
Mercury Chelation to Treat Autism
|
Phase 2 | |
Completed |
NCT02301195 -
Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder
|
N/A | |
Completed |
NCT00453180 -
A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
|
Phase 2 | |
Completed |
NCT04475848 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
|
Phase 1 | |
Terminated |
NCT01517126 -
Assessing Suicide Risk in Adolescents With Developmental Delays
|
||
Completed |
NCT00080145 -
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
|
N/A | |
Completed |
NCT00166595 -
Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)
|
Phase 1/Phase 2 | |
Completed |
NCT02124720 -
Using Mobile Technology to Reduce Stereotypy
|
N/A | |
Completed |
NCT01731119 -
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
|
Phase 2 | |
Completed |
NCT00147394 -
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
|
Phase 1 | |
Completed |
NCT01921244 -
Shared Decision Making to Improve Care and Outcomes for Children With Autism
|
N/A | |
Completed |
NCT05688319 -
Effect of Problem-Solving Training
|
N/A | |
Terminated |
NCT00445471 -
A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment
|
N/A | |
Active, not recruiting |
NCT00110708 -
Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism
|
Phase 2 |